Health Technology Assessment

70 Items

All Items

  • Budget impact analysis on the Italian healthcare system of roxadustat for the treatment of anemia due to chronic kidney disease

    Chiara Bini, Andrea Marcellusi, Paolo Di Rienzo, Lucia Del Vecchio
    175-190
    DOI: https://doi.org/10.33393/grhta.2024.3062
  • The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI

    Sergio Carbonara
    13-17
    DOI: https://doi.org/10.33393/grhta.2024.3045
  • Clinical pharmacy and telemedicine: an opportunity to improve epilepsy management

    Rossella Moscogiuri
    11-10
    DOI: https://doi.org/10.33393/grhta.2024.3095
  • Gender differences and hypercholesterolemia: real-world evidence from the study WECARE (Women Effective CArdiovascular Risk Evaluation)

    Valentina Perrone, Gerardo Medea, Stefano Urbinati, Diego Sangiorgi, Luca Degli Esposti
    138-147
    DOI: https://doi.org/10.33393/grhta.2024.2731
  • Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders

    Alicia Gil, María Reyes Abad, Carmen Alerany, Laia Alsina, Eduardo López Granados, Olaf Neth, José Luis Poveda, Jacques G. Rivière, Carlos Rodríguez-Gallego, Joanne B. Tutein Nolthenius, Raquel Figueiredo , Silvia Subías Labazuy
    124-130
    DOI: https://doi.org/10.33393/grhta.2024.3041
  • Patient-reported outcomes in epilepsy: a case study exploring their usage and impact

    Simona Lattanzi, Angela La Neve
    108-114
    DOI: https://doi.org/10.33393/grhta.2024.3020
  • Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in Italy

    Andrea Messori, Maria Rita Romeo, Valeria Fadda, Francesca Collini, Sabrina Trippoli
    105-107
    DOI: https://doi.org/10.33393/grhta.2024.3018
  • Heart failure and economic impact: an analysis in real clinical practice in Italy

    Melania Dovizio, Melania Leogrande, Luca Degli Esposti
    94-100
    DOI: https://doi.org/10.33393/grhta.2024.3013
  • The socioeconomic burden of adult attention-deficit/hyperactivity disorder in Spain

    Maria Merino, Paulina Maravilla-Herrera, Teresa Martín Lorenzo, Juan Antonio Arance, Julio Bobes, Montse Corrales, Fátima Guzmán, María Morales, Carlos Mur
    82-93
    DOI: https://doi.org/10.33393/grhta.2024.2697
  • The role and impact of health economics in the optimization of patient care in osteoarthritis: insights from a practical example

    Mickaël Hiligsmann, Olivier Bruyère
    75-81
    DOI: https://doi.org/10.33393/grhta.2024.2682
  • Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis

    Flavio Caprioli, Massimo Claudio Fantini, Francesca Marando, Dario Scaduto, Roberto Ravasio
    55-67
    DOI: https://doi.org/10.33393/grhta.2024.2658
  • Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy

    Andrea Chiricozzi, Antonio Costanzo, Anna Levi, Federica Parretta, Roberto Ravasio
    38-50
    DOI: https://doi.org/10.33393/grhta.2024.2728
  • Clinical and economic burden of peristomal skin complications: Activity Based Costing analysis

    Agostino Fortunato, Filippo Rumi, Massimo Zazzetta, Marco Della Valle, Vincenzo Pedace, Americo Cicchetti
    31-37
    DOI: https://doi.org/10.33393/grhta.2024.2639
  • A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas

    Michele Basile, Ilaria Valentini, Roberto Attanasio, Renato Cozzi, Agnese Persichetti, Irene Samperi, Alessandro Scoppola, Renata Simona Auriemma, Ernesto De Menis, Felice Esposito, Emanuele Ferrante, Giuseppe Iatì, Diego Mazzatenta, Maurizio Poggi, Roberta Rudà, Fabio Tortora, Fabio Cruciani, Zuzana Mitrova, Rosella Saulle, Simona Vecchi, Paolo Cappabianca, Agostino Paoletta, Alessandro Bozzao, Marco Caputo, Francesco Doglietto, Francesco Ferraù, Andrea Gerardo Lania, Stefano Laureti, Stefano Lello, Davide Locatelli, Pietro Maffei, Giuseppe Minniti, Alessandro Peri, Chiara Ruini, Fabio Settanni, Antonio Silvani, Nadia Veronese, Franco Grimaldi, Enrico Papini, Americo Cicchetti
    1-16
    DOI: https://doi.org/10.33393/grhta.2024.2601
  • Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2−, node-positive, high-risk early breast cancer in Italy

    Alison Davie, Sory Traoré, Massimo Giovannitti, Giuseppe Pompilio, Mark Lambton, Esra Cakar, Anuja Chatterjee
    62-69
    DOI: https://doi.org/10.33393/grhta.2023.2561
  • Good practices for the development of budget impact models at regional level

    Andrea Marcellusi, Angela Ragonese, Andrea Marinozzi, Alberto Bortolami, Sara Mucherino, Carolina Moreno, Amalia Antenori, Matteo Ferrario, Claudia Simonelli, Matteo Zanuzzi, Marco Cicoira, Ruggero Lasala, Francesco Russoniello, Francesco Attanasio, Caterina Donati, Chiara Roni, Fabrizio Gemmi, Francesco Saverio Mennini, Pierluigi Russo, Giovanna Scroccaro, PierLuigi Canonico
    53-61
    DOI: https://doi.org/10.33393/grhta.2023.2582
  • COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment

    Beatrice Canali, Laura Candelora, Francesca Fiorentino, Tom Halmos, Paola La Malfa, Francesca Massara, Chiara Vassallo, Duccio Urbinati
    46-52
    DOI: https://doi.org/10.33393/grhta.2023.2560
  • Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy

    Francesca Fiorentino, Paolo Di Rienzo
    29-39
    DOI: https://doi.org/10.33393/grhta.2023.2507
  • Cost-effectiveness of IMI/CIL/REL for the treatment of carbapenem non-susceptible Gram-negative bacterial infections

    Martina Paoletti, Andrea Marcellusi, Joe Yang, Francesco Saverio Mennini
    18-28
    DOI: https://doi.org/10.33393/grhta.2023.2488
  • Budget Impact analysis of a new system of care in Parkinson’s disease patients

    Chiara Bini, Francesco Saverio Mennini, Andrea Marcellusi, Martina Paoletti, Carlo Tomino
    91-98
    DOI: https://doi.org/10.33393/grhta.2022.2413
  • Disability weights for castration-resistant prostate cancer: an empirical investigation

    Ludovica Borsoi, Oriana Ciani, Rocco De Vivo, Giorgio Ivan Russo, Marcello Scarcia, Chiara De Fino, Patrizia Beccaglia, Irene Luccarini
    146-154
    DOI: https://doi.org/10.33393/grhta.2022.2431
  • Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy

    Giuseppe Pompilio, Davide Integlia
    138-145
    DOI: https://doi.org/10.33393/grhta.2022.2474
  • Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain

    Prof. Dr. Jaime Rodríguez Quintosa, Dr. Cintia Cristina Ago, Dr. Antoni Sicras Mainar, Dr. Renata Villoro, Dr. Inés Pérez-Román
    133-137
    DOI: https://doi.org/10.33393/grhta.2022.2439
  • Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis

    Gian Domenico Sebastiani, Marta Mosca, Roberto Ravasio, Pietro Brambilla, Paola Raimondo, Andrea Doria
    123-132
    DOI: https://doi.org/10.33393/grhta.2022.2470
  • Economic evaluation of treosulfan in patients undergoing allogeneic haematopoietic stem cell transplantation

    Chiara Bini, Martina Paoletti, Andrea Marcellusi, Carlo Tomino, Francesco Saverio Mennini
    105-116
    DOI: https://doi.org/10.33393/grhta.2022.2412
1-25 of 70